dsm-firmenich present the first worldwide results comparing their novel CBD formulation CBtru® to Epidiolex.
This Phase I clinical trial shows CBtru® offers equivalent or better bioavailability than the current gold standard, with less variability between subjects and reduced food dependency. This solid formulation breakthrough could transform CBD medication delivery with more convenient dosage options and improved patient experience.
Speaker:
This session lasts 20 min.
Taste in pediatric drug formulations shapes acceptance and adherence. Here’s what formulators need to consider to support these vulnerable patients.
Discover how dsm-firmenich and ten23 health are transforming biologic formulation development through advanced excipient options.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.